home All News open_in_new Full Article
Junshi Biosciences Announces Approval of sNDA for Toripalimab in Combination with Bevacizumab for 1st
Junshi Biosciences received NMPA approval for its sNDA for toripalimab, in combination with bevacizumab, for the first-line treatment of unresectable or metastatic hepatocellular carcinoma (HCC). The approval was based on the HEPATORCH study, which demonstrated improved PFS and OS compared to sorafenib, with a manageable safety profile. This marks the 11th approved indication for toripalimab in China.
today 44 h. ago attach_file Other
attach_file
Events
attach_file
Other
attach_file
Other
attach_file
Politics
attach_file
Economics
attach_file
Other
attach_file
Economics
attach_file
Other
attach_file
Sport
attach_file
Economics
attach_file
Other
attach_file
Other
attach_file
Other
attach_file
Economics
ID: 985585908